Genetic chips that promise to predict the outcome of cancer are rushing into the market. But are they reliable? Kris Novak reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Petricoin, E.F. et al. Lancet 359, 572–577 (2002).
Check, E. Nature 429, 496–497 (2004).
van 't Veer, L.J. et al. Nature 415, 530–536 (2002).
Paik, S. et al. N. Engl. J. Med. 351, 2817–2826 (2004).
van de Vijver, M.J. et al. N. Engl. J. Med. 347, 1999–2009 (2002).
Ransohoff, D.F. J. Natl. Canc. Inst. 97, 315–319 (2005).
Marris, E. Nat. Med. 11, 584 (2005).
Author information
Author notes
Kris Novak writes for Nature Medicine from San Francisco.
- Kris Novak
Related links
Related links
Related links in Nature Research
Proteomics and cancer: Running before we can walk?
Unchecked by government, genetic tests sell hope and hype
Related external links
Rights and permissions
About this article
Cite this article
Novak, K. News Feature: Where the chips fall. Nat Med 12, 158–159 (2006). https://doi.org/10.1038/nm0206-158
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0206-158
This article is cited by
-
Technology Insight: microarrays—research and clinical applications
Nature Clinical Practice Endocrinology & Metabolism (2007)
